What to do if you miss a dose of Alpelisib

Alpelisib (Alpelisib)-Piqray is an oral targeted drug targeting PI3Kα. It is mainly used for patients with HR-positive, HER2-negative advanced or metastatic breast cancer with PIK3CA mutations. The standard dose is 300 mg once daily, consisting of two 150 mg film-coated tablets. It should be taken with meals and should be administered at the same time every day as much as possible to maintain stable blood concentration. Regular medication is crucial for maintaining efficacy, because the drug controls tumor growth by continuously inhibiting the PI3K signaling pathway, and fluctuations in blood concentration may lead to a decrease in efficacy or an increased risk of adverse reactions.

In clinical practice, patients may occasionally miss doses. There are clear guidelines for handling missed doses. If the patient discovers that he or she has missed a dose within 9 hours of the originally scheduled dose, the patient can take the missed dose immediately with a meal. This method helps maintain continuous blood drug concentrations and ensures that efficacy is not significantly affected. If the missed dose lasts more than 9 hours, it is not recommended to make up for the day's dose. Instead, you should skip it and take it normally the next day according to the original plan. Never double your dose to make up for a missed dose. This may increase your risk of high blood sugar, rash, diarrhea, and gastrointestinal discomfort.

Research and clinical experience show that short-term single missed doses usually do not significantly weaken the overall efficacy, but frequent missed doses may lead to insufficient blood concentration, thus affecting the continuity of PI3K inhibition and the tumor control effect. To this end, patients can use methods such as reminder tools, schedule records, or pill box management to improve medication compliance. At the same time, patients should communicate with their attending physician when missing doses or adjusting doses to ensure the safety and effectiveness of the overall treatment plan. By scientifically managing missed doses, the risk of drug-related adverse events can be minimized while maintaining efficacy, providing stable and continuous treatment guarantee for patients with advanced breast cancer.

Reference materials:https://www.ncbi.nlm.nih.gov/books/NBK574353/